Lucitanib
Lucitanib (pronounced loo-si-TAN-ib) is a type of anticancer drug that is classified as a tyrosine kinase inhibitor. It is currently being studied in clinical trials for the treatment of various types of cancer, including breast cancer and lung cancer.
Etymology
The name "Lucitanib" is derived from the Latin word "lucis", meaning "light", and "tanib", which is an abbreviation for "tyrosine kinase inhibitor". The name signifies the drug's function as a beacon of hope in the fight against cancer.
Pharmacology
Lucitanib works by blocking the action of certain proteins that are involved in the growth and spread of cancer cells. These proteins include vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and platelet-derived growth factor receptor (PDGFR). By inhibiting these proteins, Lucitanib can slow down or stop the growth of cancer cells.
Clinical Trials
Lucitanib is currently being studied in several clinical trials for its effectiveness in treating various types of cancer. These trials are investigating the drug's safety, tolerability, and efficacy in patients with advanced or metastatic breast cancer, lung cancer, and other solid tumors.
Related Terms
- Anticancer drug
- Tyrosine kinase inhibitor
- Breast cancer
- Lung cancer
- Vascular endothelial growth factor receptor
- Fibroblast growth factor receptor
- Platelet-derived growth factor receptor
External links
- Medical encyclopedia article on Lucitanib
- Wikipedia's article - Lucitanib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski